Influenza/RSV immunotherapeutic.

A small molecule stimulates a highly effective host antiviral response against influenza virus and respiratory syncytial virus (RSV)

About University of Nottingham
The University of Nottingham produces world-changing research by focussing on the problems and challenges that affect societies and people on a wide scale. More than 80% of Nottingham research is ranked in the highest categories ‘world-leading’ or ‘internationally excellent’.

Background.

Flu virus readily gains resistance to current and new antivirals

Pandemics are an inevitable feature of influenza virus. Current antivirals work by directly targeting influenza virus proteins, such as viral neuraminidase and polymerase, and are highly vulnerable to resistance development due to mutations.

In such eventualities, both seasonal vaccines and existing antivirals are of limited value. Thus, there is the unmet need for antivirals to be more effective and resistant to viral mutations.

This technology developed at the University of Nottingham comprises a small molecule that stimulates a highly effective host antiviral response against influenza virus and respiratory syncytial virus (RSV) which includes interference of viral protein transport and assembly, and enhanced type I and III interferon response. The compound can be orally administered, and is difficult for virus to overcome by mutation.

Make An Enquiry.